Biological theories of depression and implications for current and new treatments

Pharmacotherapy of Depression: Second Edition

Volumn , Issue , 2011, Pages 1-32

  Goldstein, David J ^b   Potter, William Z ^a   Ciraulo, Domenic A ^c   Shader, Richard I ^d  

^a Merck Industry   (United States)

^b INDIANA UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249905792     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-435-7_1     Document Type: Chapter

References (205)

1. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry. 1983;44(8 Pt 2):8-11.
2. Gerber PD, Barrett JE, Barrett JA, Oxman TE, Manheimer E, Smith R, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med. 1992;7(2):170-3.
3. Posse M, Hallstrom T. Depressive disorders among somatizing patients in primary health care. Acta Psychiatr Scand. 1998;98(3):187-92.
4. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med. 1993;153(21):2474-80.
5. Kendler KS, Aggen SH. Time, memory and the heritability of major depression. Psychol Med. 2001;31(5):923-8.
6. Wurtman RJ. Genes, stress, and depression. Metabolism. 2005;54(5 Suppl 1):16-9.
7. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-9.
8. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxietyrelated traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527-31.
9. Hariri AR, Tessitore A, Mattay VS, Fera F, Weinberger DR. The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage. 2002;17(1):317-23.
10. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010;167(5):509-27.
11. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319-25.
12. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009;124(1):57-73.
13. Levinson DF. The genetics of depression: a review. Biol Psychiatry. 2006;60(2):84-92.
14. Warner V, Weissman MM, Fendrich M, Wickramaratne P, Moreau D. The course of major depression in the offspring of depressed parents. Incidence, recurrence, and recovery. Arch Gen Psychiatry. 1992;49(10):795-801.
15. Hammen C, Burge D, Burney E, Adrian C. Longitudinal study of diagnoses in children of women with unipolar and bipolar affective disorder. Arch Gen Psychiatry. 1990;47(12):1112-7.
16. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894-902.
17. Kendler KS, Walters EE, Neale MC, Kessler RC, Heath AC, Eaves LJ. The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry. 1995;52(5):374-83.
18. Holmes SJ, Robins LN. The influence of childhood disciplinary experience on the development of alcoholism and depression. J Child Psychol Psychiatry. 1987;28(3):399-415.
19. Magarinos AM, Deslandes A, McEwen BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999;371(2-3):113-22.
20. Kaufman J, Plotsky PM, Nemeroff CB, Charney DS. Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry. 2000;48(8):778-90.
21. Lopez JF, Akil H, Watson SJ. Neural circuits mediating stress. Biol Psychiatry. 1999;46(11):1461-71.
22. Duman RS, Charney DS. Cell atrophy and loss in major depression. Biol Psychiatry. 1999;45(9):1083-4.
23. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000;48(8):732-9.
24. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104-10.
25. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry. 2000;48(8):766-77.
26. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry. 2000;48(8):791-800.
27. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675-82.
28. Drevets WC, Price JL, Simpson JR, Jr., Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824-7.
29. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry. 2007;61(2):198-209.
30. Matthews SC, Strigo IA, Simmons AN, Yang TT, Paulus MP. Decreased functional coupling of the amygdala and supragenual cingulate is related to increased depression in unmedicated individuals with current major depressive disorder. J Affect Disord. 2008;111(1):13-20.
31. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-60.
32. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010;67(2):110-6.
33. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008; 213(1-2):93-118.
34. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets. 2006;5(4):453-79.
35. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43(4):425-73.
36. Koenig JI. Pituitary gland: neuropeptides, neurotransmitters and growth factors. Toxicol Pathol. 1989;17(2):256-65.
37. Francis DD, Caldji C, Champagne F, Plotsky PM, Meaney MJ. The role of corticotropinreleasing factor - norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress. Biol Psychiatry. 1999;46(9):1153-66.
38. McAllister-Williams RH, Ferrier IN, Young AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med. 1998;28(3):573-84.
39. Jezova D, Ochedalski T, Glickman M, Kiss A, Aguilera G. Central corticotropin-releasing hormone receptors modulate hypothalamic-pituitary- adrenocortical and sympathoadrenal activity during stress. Neuroscience. 1999;94(3):797-802.
40. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry. 1973;28(1):19-24.
41. Carroll BJ. Use of the dexamethasone suppression test in depression. J Clin Psychiatry. 1982;43(11 Pt 2):44-50.
42. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry. 1976;33(9):1051-8.
43. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry. 1985;42(12):1193-204.
44. Nathan KI, Musselman DL, Schatzberg AS, Nemeroff CB. Biology of mood disorders. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: The American Psychiatric Press; 1995. p. 439-78.
45. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984;226(4680):1342-4.
46. Gold MS, Pottash AL, Extein I. "Symptomless" autoimmune thyroiditis in depression. Psychiatry Res. 1982;6(3):261-9.
47. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med. 1986;314(21):1329-35.
48. Luo X, Kiss A, Rabadan-Diehl C, Aguilera G. Regulation of hypothalamic and pituitary corticotropin-releasing hormone receptor messenger ribonucleic acid by adrenalectomy and glucocorticoids. Endocrinology. 1995;136(9):3877-83.
49. Kant GJ, Leu JR, Anderson SM, Mougey EH. Effects of chronic stress on plasma corticosterone, ACTH and prolactin. Physiol Behav. 1987;40(6):775-9.
50. Irwin J, Ahluwalia P, Zacharko RM, Anisman H. Central norepinephrine and plasma corticosterone following acute and chronic stressors: influence of social isolation and handling. Pharmacol Biochem Behav. 1986;24(4):1151-4.
51. Stanton ME, Gutierrez YR, Levine S. Maternal deprivation potentiates pituitary-adrenal stress responses in infant rats. Behav Neurosci. 1988;102(5):692-700.
52. Levine S, Atha K, Wiener SG. Early experience effects on the development of fear in the squirrel monkey. Behav Neural Biol. 1993;60(3):225-33.
53. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Prog Brain Res. 2000;122:25-34.
54. Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry. 1998; 43(8):547-73.
55. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry. 1996;53(2):137-43.
56. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry. 1995;152(9):1372-6.
57. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93(9):3908-13.
58. MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A. 2003;100(3):1387-92.
59. Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5(5):1222-7.
60. Bremner JD. Does stress damage the brain? Biol Psychiatry. 1999;45(7):797-805.
61. Ohgoh M, Kimura M, Ogura H, Katayama K, Nishizawa Y. Apoptotic cell death of cultured cerebral cortical neurons induced by withdrawal of astroglial trophic support. Exp Neurol. 1998;149(1):51-63.
62. Gould E, Tanapat P. Stress and hippocampal neurogenesis. Biol Psychiatry. 1999;46(11): 1472-9.
63. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4(11):1313-7.
64. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007;10(9):1110-5.
65. Alexopoulos GS, Young RC, Meyers BS, Abrams RC, Shamoian CA. Late-onset depression. Psychiatr Clin North Am. 1988;11(1):101-15.
66. Koenderink MJ, Uylings HB, Mrzljak L. Postnatal maturation of the layer III pyramidal neurons in the human prefrontal cortex: a quantitative Golgi analysis. Brain Res. 1994; 653(1-2):173-82.
67. Young LT. Postreceptor pathways for signal transduction in depression and bipolar disorder. J Psychiatry Neurosci. 2001;26(Suppl):S17-22.
68. Uno H, Tarara R, Else JG, Suleman MA, Sapolsky RM. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci. 1989;9(5):1705-11.
69. Watanabe Y, Gould E, McEwen BS. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992;588(2):341-5.
70. Endo Y, Nishimura JI, Kobayashi S, Kimura F. Chronic stress exposure influences local cerebral blood flow in the rat hippocampus. Neuroscience. 1999;93(2):551-5.
71. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev. 1986;7(3):284-301.
72. Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 1990;10(9):2897-902.
73. Woolley CS, Gould E, McEwen BS. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res. 1990;531(1-2):225-31.
74. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry. 1992;32(9):756-65.
75. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157(1):115-8.
76. Herman JP, Schafer MK, Young EA, Thompson R, Douglass J, Akil H, et al. Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamo-pituitary-adrenocortical axis. J Neurosci. 1989;9(9):3072-82.
77. Feldman S, Conforti N. Participation of the dorsal hippocampus in the glucocorticoid feedback effect on adrenocortical activity. Neuroendocrinology. 1980;30(1):52-5.
78. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry. 1998;172:527-32.
79. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu Rev Neurosci. 1999;22:295-318.
80. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15(3 Pt 1):1768-77.
81. Hashimoto K. Brain derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010;64:341-57.
82. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22(8):3251-61.
83. Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet. 1998; 352(9142):1754-5.
84. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16(7):2365-72.
85. Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(6):881-8.
86. Palmer TD, Takahashi J, Gage FH. The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci. 1997;8(6):389-404.
87. Sulser F. The role of CREB and other transcription factors in the pharmacotherapy and etiology of depression. Ann Med. 2002;34(5):348-56.
88. Holsboer F. Current theories on the pathophysiology of mood disorders. In: Montgomery SA, Halbreich U, editors. Pharmacology for Mood, Anxiety, and Cognitive Disorders. Washington, DC: The American Psychiatric Press; 2000. p. 13-35.
89. Prange AJ, Loosen PT, Wilson IC. The therapeutic use of hormones of the thyroid axis in depression. In: Post RM, Ballenger JC, editors. Neurobiology of Mood Disorders, Frontiers of Clinical Neuroscience. New York: Marcel Dekker; 1990. p. 311-20.
90. Bauer MS, Whybrow PC, Winokur A. Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism. Arch Gen Psychiatry. 1990;47(5):427-32.
91. Mendlewicz J, Linkowski P, Kerkhofs M, Desmedt D, Golstein J, Copinschi G, et al. Diurnal hypersecretion of growth hormone in depression. J Clin Endocrinol Metab. 1985;60(3):505-12.
92. Powell LH, Lovallo WR, Matthews KA, Meyer P, Midgley AR, Baum A, et al. Physiologic markers of chronic stress in premenopausal, middle-aged women. Psychosom Med. 2002;64(3):502-9.
93. Siever LJ, Uhde TW, Jimerson DC, Lake CR, Silberman ER, Post RM, et al. Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. Am J Psychiatry. 1984;141(6):733-41.
94. Amsterdam JD, Maislin G, Skolnick B, Berwish N, Winokur A. Multiple hormone responses to clonidine administration in depressed patients and healthy volunteers. Biol Psychiatry. 1989;26(3):265-78.
95. Laakmann G, Hinz A, Voderholzer U, Daffner C, Muller OA, Neuhauser H, et al. The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients. Pharmacopsychiatry. 1990;23(1):18-26.
96. Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res. 1986;20(3):175-93.
97. Rubinow DR, Gold PW, Post RM, Ballenger JC, Cowdry R, Bollinger J, et al. CSF somatostatin in affective illness. Arch Gen Psychiatry. 1983;40(4):409-12.
98. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry. 1985;142(9):1017-31.
99. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord. 1990;19(1):43-51.
100. O'Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry. 1991;148(8):1009-15.
101. Price LH, Charney DS, Delgado PL, Heninger GR. Serotonin function and depression: neuroendocrine and mood responses to intravenous l-tryptophan in depressed patients and healthy comparison subjects. Am J Psychiatry. 1991;148(11):1518-25.
102. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, et al. Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients. Psychiatry Res. 1990;31(1):39-47.
103. Golden RN, Ekstrom D, Brown TM, Ruegg R, Evans DL, Haggerty JJ, Jr., et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry. 1992;149(9):1168-75.
104. Kripke DF. Critical interval hypotheses for depression. Chronobiol Int. 1984;1(1):73-80.
105. Lewy AJ. Circadian phase sleep and mood disorders. In: David KL, Charney DS, Coyle JT, Nemeroff CB, editors. Neuropsychopharmacology, The Fifth Generation of Progress. New York: Lippincott Williams & Wilkins; 2002. p. 1879-93.
106. Petitto JM, Folds JD, Ozer H, Quade D, Evans DL. Abnormal diurnal variation in circulating natural killer cell phenotypes and cytotoxic activity in major depression. Am J Psychiatry. 1992;149(5):694-6.
107. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebocontrolled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry. 2008;165(5):617-20.
108. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509-22.
109. Blier P, de Montigny C. Clarifications on the effects of 5-HT1A agonists and selective 5-HT reuptake inhibitors on the 5-HT system. Neuropsychopharmacology. 1996;15(2):213-6.
110. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19(9):378-83.
111. Levine LR, Potter WZ. The 5HT1A receptor: an unkept promise? Curr Opin CNS Invest Drugs. 1999;1:448-52.
112. Griffith R, Sutin J. Reactive astrocyte formation in vivo is regulated by noradrenergic axons. J Comp Neurol. 1996;371(3):362-75.
113. Marek GJ. A novel approach to the identification of psychiatric drugs; serotonin-glutamate interactions in the prefrontal cortex. CNS Drug Rev. 2000;6:206-18.
114. Baker KG, Halliday GM, Hornung JP, Geffen LB, Cotton RG, Tork I. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience. 1991;42(3):757-75.
115. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther. 2001;299(2):449-58.
116. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry. 1994;51(11):865-74.
117. Nishizawa S, Benkelfat C, Young S. Differences between male and female in rates of seretonin synthesis in human brain. Proc Natl Acad Sci U S A. 1997;94:5308-13.
118. Ellis PM, Salmud C. Is platelet imipramine binding reduced in depression? A meta-analysis. Biol Psychiatry. 1994;36:292-9.
119. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology. 1997;16(2):162-73.
120. Staley KJ, Longacher M, Bains JS, Yee A. Presynaptic modulation of CA3 network activity. Nat Neurosci. 1998;1(3):201-9.
121. Fujita M, Charney DS, Innis RB. Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations. Biol Psychiatry. 2000;48(8):801-12.
122. Linnoila VM, Virkkunen M. Aggression, suicidality, and serotonin. J Clin Psychiatry. 1992;53(Suppl):46-51.
123. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA. 1998;95(24):14476-81.
124. Julius D. Serotonin receptor knockouts: a moody subject. Proc Natl Acad Sci USA. 1998;95(26):15153-4.
125. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A. 1998;95(25):15049-54.
126. Miller HL, Delgado PL, Salomon RM, Heninger GR, Charney DS. Effects of alphamethyl- para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology. 1996;14(3):151-7.
127. Woodward DJ, Moises HC, Waterhouse BD, Hoffer BJ, Freedman R. Modulatory actions of norepinephrine in the central nervous system. Fed Proc. 1979;38(7):2109-16.
128. Aston-Jones G. Norepinephrine. In: David K, Charney DS, Coyle JT, Nemeroff CB, editors. The Fifth Generation of Progress. New York: Lippincott Williams & Wilkins; 2002. p. 47-58.
129. Abercrombie ED, Jacobs BL. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. I. Acutely presented stressful and nonstressful stimuli. J Neurosci. 1987;7(9):2837-43.
130. Hellhammer DH, Hingtgen JN, Wade SE, Shea PA, Aprison MH. Serotonergic changes in specific areas of rat brain associated with activity - stress gastric lesions. Psychosom Med. 1983;45(2):115-22.
131. Lehnert H, Reinstein DK, Strowbridge BW, Wurtman RJ. Neurochemical and behavioral consequences of acute, uncontrollable stress: effects of dietary tyrosine. Brain Res. 1984;303(2):215-23.
132. Rosenblatt S, Chanley JD, Leighton WP. The investigation of adrenergic metabolism with 7H3-norepinephrine in psychiatric disorders. II. Temporal changes in the distribution of urinary tritiated metabolites in affective disorders. J Psychiatr Res. 1969;6(4):321-33.
133. Potter WZ, Manji HK. Catecholamines in depression: an update. Clin Chem. 1994; 40(2):279-87.
134. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and TrkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15(11):7539-47.
135. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997;17(8):2785-95.
136. Rajkowska G. Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res. 2000;126:397-412.
137. Manier DH, Shelton RC, Sulser F. Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P? J Neural Transm. 2002;109(1):91-9.
138. Osman O, Potter W. Potentiation of dopamine in the treatment of refractory depression. In: Amsterdam JD, editor. Advances in Neuropsychiatry and Psychopharmacology: Refractory Depression. New York: Raven; 1991. p. 41-52.
139. Wilner P. Dopaminergic mechanisms in depression and mania. In: Bloom F, Kupfer D, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven; 1995. p. 921-31.
140. Rush AJ, Ryan N. Current and emerging therpeutics for depression. In: Davis K, Harney D, Coyle J, Nemeroff CB, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. p. 1081-95.
141. Garlow S, Musselman D, Nemreoff C. The neurochemistry of mood disorders: clinical studies. In: Davison R, Post R, editors. Neurobiology of Mental Illness. New York: Oxford Press; 1999. p. 348-64.
142. Roy A, Pickar D, Douillet P, Karoum F, Linnoila M. Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. Psychol Med. 1986;16(3):541-6.
143. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS. CSF amine metabolites in depression. Biol Psychiatry. 1992;31(2):112-8.
144. D'Haenen H A, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 1994;35(2):128-32.
145. Ebert D, Feistel H, Loew T, Pirner A. Dopamine and depression - striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl). 1996;126(1):91-4.
146. Larish R, Klimke A, Vosberg H, Gaebel W, Mueller-Gaertner HW. Cingulate function in depression. Neuroreport. 1997;8(15):i-ii.
147. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002; 52(7):740-8.
148. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res. 2002;58:169-222.
149. Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL. Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Neuropsychopharmacology. 1999;21(3): 399-407.
150. Lyons DM, Lopez JM, Yang C, Schatzberg AF. Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys. J Neurosci. 2000;20(20):7816-21.
151. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-57.
152. Baune BT, Dannlowski U, Domschke K, Janssen DG, Jordan MA, Ohrmann P, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry. 2010;67(6):543-9.
153. Mantyh PW, Hunt SP, Maggio JE. Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res. 1984;307(1-2):147-65.
154. Arai H, Emson PC. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res. 1986;399(2):240-9.
155. Hokfrlt T, Johansson O, Holets VR, Meister B, Melander T. Distribution of neuropeptides with special reference to their coexistence with clasical transmitters. In: Meltzer H, editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987. p. 401-16.
156. Chang HM, Wang L, Zhang XP, Kream RM, Yeh ET. Modulation of substance P release in primary sensory neurons by misoprostol and prostaglandins. Am J Ther. 1996;3(4):276-9.
157. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A. 2002;99(12):8400-5.
158. Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry. 2001;50(3):191-9.
159. Liu R, Ding Y, Aghajanian GK. Neurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. Neuropsychopharmacology. 2002;27(3):329-40.
160. Millan MJ, Lejeune F, De Nanteuil G, Gobert A. Selective blockade of neurokinin (NK) (1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem. 2001;76(6):1949-54.
161. File SE. Anxiolytic action of a neurokinin 1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav. 1997;58(3):747-52.
162. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281(5383):1640-5.
163. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. 2000;39(8):1413-21.
164. Takayama H, Ota Z, Ogawa N. Effect of immobilization stress on neuropeptides and their receptors in rat central nervous system. Regul Pept. 1986;15(3):239-48.
165. Bannon MJ, Deutch AY, Tam SY, Zamir N, Eskay RL, Lee JM, et al. Mild footshock stress dissociates substance P from substance K and dynorphin from Met- and Leu-enkephalin. Brain Res. 1986;381(2):393-6.
166. Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, Hagan RM. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology (Berl). 1995;121(2):186-91.
167. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59(3):216-23.
168. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48(8):755-65.
169. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-d-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995;675(1-2):157-64.
170. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 1994;269(1):95-102.
171. Skolnick P, Miller R, Young A, Boje K, Trullas R. Chronic treatment with 1 aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyld- aspartate receptor complex. Psychopharmacology (Berl). 1992;107(4):489-96.
172. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.
173. Rogoz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002;42(8):1024-30.
174. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
175. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN. 5HT2 receptor changes in major depression. Biol Psychiatry. 1990;27(5):489-96.
176. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, et al. Tryptophandepletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. 1999;46(2):212-20.
177. Shiffer HH. Glutamate receptor genes: susceptibility factors in schizophrenia and depressive patients. Mol Biol. 2002;25:191-212.
178. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord. 1995;34(4):275-81.
179. Lloyd KG, Thuret F, Pilc A. Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther. 1985;235(1):191-9.
180. Kimber JR, Cross JA, Horton RW. Benzodiazepine and GABAA receptors in rat brain following chronic antidepressant drug administration. Biochem Pharmacol. 1987;36(23):4173-5.
181. Liu R, Jolas T, Aghajanian G. Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res. 2000;873(1):34-45.
182. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999;156(12):2017.
183. Akbarian S, Rios M, Liu RJ, Gold SJ, Fong HF, Zeiler S, et al. Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J Neurosci. 2002;22(10):4153-62.
184. Sher L. The placebo effect on mood and behavior: the role of the endogenous opioid system. Med Hypotheses. 1997;48(4):347-9.
185. Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain. 2001;90(3):205-15.
186. Cardinali DP. The human body circadian: how the biologic clock influences sleep and emotion. Neuro Endocrinol Lett. 2000;21(1):9-15.
187. Bunney WE, Bunney BG. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology. 2000;22(4):335-45.
188. Lewy AJ, Bauer VK, Cutler NL, Sack RL, Ahmed S, Thomas KH, et al. Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry. 1998;55(10):890-6.
189. Nofzinger EA, Price JC, Meltzer CC, Buysse DJ, Villemagne VL, Miewald JM, et al. Towards a neurobiology of dysfunctional arousal in depression: the relationship between beta EEG power and regional cerebral glucose metabolism during NREM sleep. Psychiatry Res. 2000;98(2):71-91.
190. Nofzinger EA, Mintun MA, Wiseman M, Kupfer DJ, Moore RY. Forebrain activation in REM sleep: an FDG PET study. Brain Res. 1997;770(1-2):192-201.
191. Clark CP, Frank LR, Brown GG. Sleep deprivation, EEG, and functional MRI in depression: preliminary results. Neuropsychopharmacology. 2001;25(5 Suppl):S79-84.
192. Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am. 2002;31(1):15-36.
193. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A metaanalysis. Arch Gen Psychiatry. 1992;49(8):651-68; discussion 69-70.
194. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(18):1329-35.
195. Stahl SM. Does depression hurt? J Clin Psychiatry. 2002;63(4):273-4.
196. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24(4):389-99.
197. Petrovic P, Ingvar M. Imaging cognitive modulation of pain processing. Pain. 2002; 95(1-2):1-5.
198. Yu J, Smith GP. Affinity maturation of phage-displayed peptide ligands. Methods Enzymol. 1996;267:3-27.
199. Gamaro GD, Manoli LP, Torres IL, Silveira R, Dalmaz C. Effects of chronic variate stress on feeding behavior and on monoamine levels in different rat brain structures. Neurochem Int. 2003;42(2):107-14.
200. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev. 1999;20(1):68-100.
201. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18(4):289-99.
202. Nelson JC, Mazure CM, Bowers MB, Jr., Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303-7.
203. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62(11):869-77.
204. Malhi GS, Moore J, McGuffin P. The genetics of major depressive disorder. Curr Psychiatry Rep. 2000;2(2):165-9.
205. Yamada M, Higuchi T. Functional genomics and depression research. Beyond the monoamine hypothesis. Eur Neuropsychopharmacol. 2002;12(3):235-44.